Trial Profile

AntiRetroviral Research fOr Watoto.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abacavir (Primary) ; Antiretrovirals; Cotrimoxazole; Efavirenz; Lamivudine; Lamivudine/abacavir; Nevirapine; Zidovudine
Indications HIV-1 infections
Focus Adverse reactions; Therapeutic Use
Acronyms ARROW; ARROW

Most Recent Events

06 Mar 2024 Results (n=497) assessing associations between CMV Viraemia and mortality in children with HIV in sub-saharan africa were presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
07 Mar 2013 Primary endpoint 'Disease-progression' has been met according to results published in the Lancet; non inferiority of clinical over laboratory monitoring was established.
07 Mar 2013 Primary endpoint 'CD4+-cell-percentage' has not been met according to results published in the Lancet.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com